Symposia: Aggressive Lymphomas: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Adult, Non-Hodgkin lymphoma, Lymphomas, Translational Research, Epidemiology, Clinical Practice (Health Services and Quality), Clinical Research, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Health outcomes research, Diseases, Real-world evidence, Aggressive lymphoma, Treatment Considerations, Biological therapies, Registries, Lymphoid Malignancies, Biological Processes, Technology and Procedures, Study Population, Human, Measurable Residual Disease , Pathology
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Adult, Non-Hodgkin lymphoma, Lymphomas, Translational Research, Epidemiology, Clinical Practice (Health Services and Quality), Clinical Research, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Health outcomes research, Diseases, Real-world evidence, Aggressive lymphoma, Treatment Considerations, Biological therapies, Registries, Lymphoid Malignancies, Biological Processes, Technology and Procedures, Study Population, Human, Measurable Residual Disease , Pathology
Sunday, December 8, 2024: 9:30 AM-11:00 AM
Marriott Grand Ballroom 8-9
(Marriott Marquis San Diego Marina)
Moderators:
Thomas Stauffer Larsen, MD, PhD, ARRAY(0xe93e210)
and
Dai Chihara, MD, PhD, National Institute of Health
Disclosures:
Chihara: BMS: Research Funding; Genentech: Research Funding; Ono pharmaceutical: Research Funding; Genmab: Research Funding; BeiGene: Honoraria; SymBio pharmaceutical: Honoraria.
In this session longer term follow-up and additional analyses on recent strategies for treatment of aggressive b-cell lymphoma will be presented.
9:30 AM
9:45 AM
10:00 AM
10:15 AM
10:30 AM
10:45 AM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH